The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The firm will use the funds to advance its mRNA therapies, including its lead candidate STX-001 for treating melanoma and triple-negative breast cancer.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

NEW YORK – Patients with previously treated, advanced urothelial cancer with high expression of PPARG are starting to receive Flare Therapeutics' investigational drug FX-909 in a Phase Ib trial, the ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.